Brief: Casi Pharma Exits Juventas Investment To Strengthen Balance Sheet
23/09/2022 12:12
Sept 23 (Reuters) - CASI Pharmaceuticals Inc CASI.O :
* CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT
TO
STRENGTHEN BALANCE SHEET
* CASI PHARMACEUTICALS INC - CASI WUXI AGREED TO TRANSFER
ITS
EQUITY INTEREST IN JUVENTAS BIOTECHNOLOGY
* CASI PHARMACEUTICALS INC - PROPOSED DEAL FOR RMB 240.87
MILLION
Source text for Eikon: ID:nPn2d6rJna
Further company coverage: CASI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CASI Pharmaceuticals
See all newsBrief: Casi Pharmaceuticals Reports The Receipt Of Drug Registration Certificate For Thiotepa In China
CASI Pharmaceuticals Q3 revenue drops 60%, net loss widens
Brief: CASI Pharmaceuticals Inc Reports The Expiration Of Import Drug Registration License For Folotyn® In China
Casi Pharmaceuticals Inc Expected To Post A Loss Of 47 Cents A Share: Earnings Preview
Casi Pharmaceuticals Inc Reports Results For The Quarter Ended March 31: Earnings Summary